Glycogen Storage Disease Type Ia (GSDIa) Disease Monitoring Program
Ориентир для пациента и семьи
Простыми словами
Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.
- Что изучают
- В протоколе указаны: No Intervention.
- Кому может быть актуально
- Состояния в реестре: Glycogen Storage Disease Type Ia. Базовые параметры: от 2 лет · Все.
- Что важно проверить
- Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
- Где проводится
- США, Бразилия, Канада, Дания, Германия +4
- Следующий шаг
- Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →
Не всё понятно в терминах? Прочитайте наш гид для пациентов →
Официальное название
GSDIa Disease Monitoring Program
Обзор
The main objective of this observational study is to evaluate the long-term safety and effectiveness of DTX401 for at least 10 years after DTX401 administration.
Подробное описание
The DTX401-CL401 Disease Monitoring Program (DMP) is a prospective, multicenter, long-term observational study to follow up participants with GSDIa for at least 10 years after the administration of DTX401.
Вмешательства
- Другое No Intervention
No investigational/study product will be administered in this DMP.
Первичные конечные точки
- Incidence and Severity of Serious Adverse Events (SAEs) Assessed as Related to DTX401 by the Investigator [Срок оценки: 10 Years]
- Incidence, Relationship, Severity and Seriousness of Adverse Events of Special Interest (AESIs) for Adeno-Associated Virus (AAV) Therapies [Срок оценки: 10 Years]
- Incidence of Pregnancy in Patients Treated with DTX401 or Patient's Partner [Срок оценки: 10 Years]
- Outcomes of Pregnancy in Patients Treated with DTX401 or Patient's Partner [Срок оценки: 10 Years]
- Incidence and Severity of SAEs of Infusion-Related Reactions Including Hypersensitivity (Group 2 only) [Срок оценки: 1 Year]
- Incidence and Severity of SAEs Assessed by the Investigator as Related to Concomitant Immunomodulatory Therapies (Group 2 only) [Срок оценки: 1 Year]
Вторичные конечные точки (12)
- Percent Change Over Time from Baseline in Total Cornstarch Intake [Срок оценки: Baseline, Up to 10 Years]
- Change from Baseline Over Time in Frequency of Cornstarch Intake [Срок оценки: Baseline, Up to 10 Years]
- Change from Baseline Over Time in Number of Nighttime Awakenings for Cornstarch [Срок оценки: Baseline, Up to 10 Years]
- Change from Baseline Over Time in Dependance on Continuous Overnight Tube Feeding for Exogenous Glucose Delivery [Срок оценки: Baseline, Up to 10 Years]
- Change from Baseline Over Time in Daily Dietary Intake of Foods, Beverages, and Medical Foods/Formulas (Non-Cornstarch) [Срок оценки: Baseline, Up to 10 Years]
- Change from Baseline Over Time in Daytime and Nighttime Percentage of Glucose Values During the 2 Weeks Leading Up to the Assessment Visits [Срок оценки: Baseline, Up to 10 Years]
- Change from Baseline Over Time in Total Number of Hypoglycemic Events on Continuous Glucose Monitoring (CGM) During the 2 Weeks Leading Up to the Assessment Visits [Срок оценки: Baseline, Up to 10 Years]
- Change from Baseline Over Time in Total Duration of Hypoglycemic Events on CGM During the 2 Weeks Leading Up to the Assessment Visits [Срок оценки: Baseline, Up to 10 Years]
- Change from Baseline Over Time in Real-World Overnight Fasting Tolerance [Срок оценки: Baseline, Up to 10 Years]
- Change from Baseline Over Time in Metabolic and GSDIa Related Parameters: Height [Срок оценки: 10 Years]
- Change from Baseline Over Time in Metabolic and GSDIa Related Parameters: Weight [Срок оценки: 10 Years]
- Change from Baseline Over Time in Metabolic and GSDIa Related Parameters: Body Mass Index (BMI) [Срок оценки: 10 Years]
Критерии участия
Критерии включения
- Patient who had:
- DTX401 (full or partial dose) administered in a parent clinical study (Group 1) or
- Prescribed DTX401(full or partial dose) administered in a post-marketing setting (Group 2)
- Patient is willing and able to provide informed consent after the nature of the study has been explained, and prior to any research-related assessments or procedures. If a minor or an adult with cognitive limitations, the patient is willing and able (if possible) to provide assent and have a legally authorized representative provide informed consent after the nature of the study has been explained, and prior to any research-related assessments or procedures.
Критерии исключения
- Presence of any condition that would interfere with study participation, interpretation of results or affect patient's safety in the opinion of the Investigator
Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.
Здоровые добровольцы: Нет
Дизайн исследования
- Модель наблюдения
- Когортное
Центры проведения
США · 9 центров
- Children's Hospital of Orange County — Orange
- Children's Hospital Colorado — Denver
- University of Connecticut Health Center — Hartford
- University of Michigan — Ann Arbor
- Duke University Medical Center — Durham
- The Cleveland Clinic Foundation — Cleveland
- Children's Hospital of Philadelphia — Philadelphia
- University of Texas Health Science Center at Houston — Houston
- … и ещё 1 центр
Италия · 2 центра
- University of Naples — Naples
- Istituto G Gaslini Ospedale Pediatrico IRCCS — Genoa
Япония · 2 центра
- Osaka City General Hospital — Osaka
- Fujita Health University Hospital — Toyoake
Бразилия · 1 центр
- Hospital de Clinicas de Porto Alegre (HCPA) - PPDS — Porto Alegre
Канада · 1 центр
- McGill University Health Center — Montreal
Дания · 1 центр
- Rigshospitalet — Copenhagen
Германия · 1 центр
- Universitätsklinikum Hamburg Eppendorf — Hamburg
Нидерланды · 1 центр
- Groningen University — Groningen
Испания · 1 центр
- Hospital Clínico Universitario de Santiago — Santiago
Идентификаторы
NCT: NCT06636383 · DTX401-CL401 · 2023-510219-20-00